- Sonoma Pharmaceuticals press release ( NASDAQ: SNOA ): Q1 GAAP EPS of -$0.29.
- Revenue of $3.99M (+8.4% Y/Y).
For further details see:
Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99MFor further details see:
Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Sonoma Pharmaceuticals Inc. Company Name:
SNOA Stock Symbol:
Market:
Sonoma Pharmaceuticals Inc. Website:
BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasa...
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal ...
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal...